At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Axitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 15, 2011·Updated Oct 2, 2018
In Brief
A Phase 2 clinical trial evaluating Axitinib for Carcinoid Tumor. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Tumor
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network, Pfizer
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionJan 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedSep 15, 2011
Enrollment StartOct 25, 2011
Primary CompletionJan 11, 2017
Study CompletionFeb 13, 2018
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 14.8 years ago
Interventions
Axitinibdrug
Axitinib Administration as outlined in Arm description